Evolution of hormonal therapy for prostate cancer
Details
Publication Year 2024-05,Volume 53,Issue #5,Page 291-300
Journal Title
Australian Journal of General Practice
Publication Type
Review
Abstract
BACKGROUND: Prostate cancer (PCa) is the most common malignancy after skin cancer in men in Australia. Its management varies according to tumour stage. Due to the significant dependence on androgen receptor signalling, agents that interfere with this pathway (most commonly medical castration in the form of androgen deprivation therapy [ADT]) are the mainstay treatment of advanced disease. OBJECTIVE: This review provides a contemporary update on ADT, with further discussion of emerging novel therapies for primary care. DISCUSSION: ADT is currently indicated for the treatment of metastatic prostate cancer, disease recurrence following attempted local curative therapy, as well as combined use with radiotherapy for intermediate/high-risk disease. There has been rapid development of new pharmaceuticals targeting the androgen receptor. These are reviewed historically with an emphasis placed on emerging therapies, their common side effects, and how to manage them in the general practice setting.
Publisher
RACGP
Keywords
Humans; Male; *Prostatic Neoplasms/drug therapy; *Androgen Antagonists/therapeutic use; Antineoplastic Agents, Hormonal/therapeutic use/pharmacology; Australia
Department(s)
Medical Oncology
Open Access at Publisher's Site
https://doi.org/10.31128/ajgp-11-23-7028
Terms of Use/Rights Notice
Refer to copyright notice on published article.


Creation Date: 2024-07-09 08:01:44
Last Modified: 2024-07-09 08:03:53

© 2024 The Walter and Eliza Hall Institute of Medical Research. Access to this website is subject to our Privacy Policy and Terms of Use

An error has occurred. This application may no longer respond until reloaded. Reload 🗙